Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Journal of Clinical Investigation

• Publication date

  2001-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI11537PMID 11696577PMCID PMC209432
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromosomal Translocation t ( l 5 ; 17 ) in Human Acute Promyelocytic Leukemia Fuses RARa with a Novel Putative Transcription Factor , PML

  2003cited by this paper
• Acute Promyelocytic Leukemia

  2002cited by this paper
• Clinical and Molecular Characterization of a Rare Syndrome of Acute Promyelocytic Leukemia Associated With Translocation

  2002influential reference
• Transcription therapy for cancer

  2001cited by this paper
• Molecular mechanisms of corepressor function.

  2001influential reference
• Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.

  2001cited by this paper
• Avian erythroleukemia: a model for corepressor function in cancer

  2001cited by this paper
• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.

  2000cited by this paper
• Two critical hits for promyelocytic leukemia.

  2000cited by this paper
• Targeting of N‐CoR and histone deacetylase 3 by the oncoprotein v‐ErbA yields a chromatin infrastructure‐dependent transcriptional repression pathway

  2000cited by this paper
• Rearrangements of the BCL 6 Gene in Diffuse Large Cell Non-Hodgkin ’ s Lymphoma

  2000cited by this paper
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

  2000cited by this paper
• Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins.

  2000cited by this paper
• Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia

  1999cited by this paper
• Histone Deacetylase Inhibition Selectively Alters the Activity and Expression of Cell Cycle Proteins Leading to Specific Chromatin Acetylation and Antiproliferative Effects*

  1999cited by this paper
• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

  1999cited by this paper
• Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.

  1999cited by this paper
• The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor alpha in acute promyelocytic-like leukaemia.

  1999cited by this paper
• Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase

  1999cited by this paper
• Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).

  1999cited by this paper
• In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications

  1999cited by this paper
• Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation.

  1999cited by this paper
• Complete Remission after Treatment of Acute Promuelocytic Leukemia with Arsenic Trioxide

  1999cited by this paper
• Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation.

  1999cited by this paper
• A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

  1999cited by this paper
• Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL

  1998cited by this paper
• Retinoblastoma protein represses transcription by recruiting a histone deacetylase

  1998cited by this paper
• Retinoblastoma protein recruits histone deacetylase to repress transcription

  1998cited by this paper
• Role of the histone deacetylase complex in acute promyelocytic leukaemia

  1998cited by this paper
• Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia

  1998cited by this paper
• FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

  1998cited by this paper
• Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.

  1998cited by this paper
• Rb interacts with histone deacetylase to repress transcription.

  1998cited by this paper
• Aberrant Recruitment of the Nuclear Receptor Corepressor-Histone Deacetylase Complex by the Acute Myeloid Leukemia Fusion Partner ETO

  1998cited by this paper
• Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

  1998cited by this paper
• ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

  1998cited by this paper
• Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.

  1998influential reference
• A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

  1998influential reference
• Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.

  1998cited by this paper
• Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.

  1997cited by this paper
• A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression

  1997cited by this paper
• Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukaemia

  1997influential reference
• Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.

  1997cited by this paper
• Histone acetylation in chromatin structure and transcription

  1997cited by this paper
• Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression

  1997cited by this paper
• Acute leukemia with promyelocytic features in PML/RARα transgenic mice

  1997cited by this paper
• A decade of molecular biology of retinoic acid receptors

  1996cited by this paper
• New York, New York, USA

  1996cited by this paper
• The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation.

  1996cited by this paper
• Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase.

  1996cited by this paper
• The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

  1996cited by this paper
• Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase.

  1996cited by this paper
• Unliganded thyroid hormone receptor alpha can target TATA-binding protein for transcriptional repression

  1996cited by this paper
• Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17).

  1995cited by this paper
• Trichostatin A and trapoxin: Novel chemical probes for the role of histone acetylation in chromatin structure and function

  1995cited by this paper
• Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma.

  1995cited by this paper
• A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V.

  1995cited by this paper
• Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.

  1994cited by this paper
• WAF1, a potential mediator of p53 tumor suppression.

  1993cited by this paper
• Rearrangements of the retinoic acid receptor alpha and promyelocytic leukemia zinc finger genes resulting from t(11;17)(q23;q21) in a patient with acute promyelocytic leukemia.

  1993cited by this paper
• Fusion between a novel Krüppel‐like zinc finger gene and the retinoic acid receptor‐alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia.

  1993cited by this paper
• Acute promyelocytic leukemia.

  1993cited by this paper
• Retinoids in cancer therapy.

  1992cited by this paper
• Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties.

  1991cited by this paper
• Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).

  1991cited by this paper
• Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia.

  1991cited by this paper
• The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

  1991cited by this paper
• Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

  1987cited by this paper
• Cellular biology and biochem-istry of the retinoids

  1984cited by this paper
• Effects of sodium butyrate, a new pharmacological agent, on cells in culture

  1981cited by this paper

• Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy

  2025cites this paper
• CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia

  2025cites this paper
• Successfully treatment of PLZF-RARα positive acute promyelocytic leukemia by Venetoclax combining with decitabine: a case report and literature review

  2024cites this paper
• Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies.

  2024cites this paper
• Acute Promyelocytic Leukemia-like AML: Genetic Perspective and Clinical Implications

  2024cites this paper
• Function of PML-RARA in Acute Promyelocytic Leukemia.

  2024cites this paper
• Extirpating the cancer stem cell hydra: Differentiation therapy and Hyperthermia therapy for targeting the cancer stem cell hierarchy

  2023cites this paper
• Acetylation stabilizes the signaling protein WISP2 by preventing its degradation to suppress the progression of acute myeloid leukemia

  2023cites this paper
• The Role of epigenetic modifications of DNA and histones in the treatment of oncohematological diseases

  2021cites this paper
• Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma

  2021cites this paper
• Current views on the genetic landscape and management of variant acute promyelocytic leukemia

  2021influential citation
• Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities.

  2020cites this paper
• Retinoid Pharmacology, an Old Hot Topic: Discussion on Retinoic Acid Action in APL

  2020cites this paper
• Present and future perspectives for targeting histone modifications in therapy

  2020cites this paper
• Retinoic acid signaling and bladder cancer: Epigenetic deregulation, therapy and beyond

  2020cites this paper
• Classic and Variants APLs, as Viewed from a Therapy Response

  2020cites this paper
• Effect of sodium butyrate on HDAC8 mRNA expression in colorectal cancer cell lines and molecular docking study of LHX1 - sodium butyrate interaction

  2020cites this paper
• Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia

  2020cites this paper
• HDAC Inhibitors in Acute Myeloid Leukemia

  2019influential citation
• Advances in precision epigenetic treatment for acute promyelocytic leukemia.

  2019influential citation
• Effect of Sodium Butyrate on LHX1 mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines

  2019cites this paper
• Mechanism of Action for HDAC Inhibitors—Insights from Omics Approaches

  2019cites this paper
• Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling

  2018cites this paper
• ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation

  2018cites this paper
• miR-124-3p is a chronic regulator of gene expression after brain injury

  2018cites this paper
• Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs

  2017cites this paper
• Novel epigenetic therapies in hematological malignancies: Current status and beyond.

  2017cites this paper
• Acetylation- and Methylation-Related Epigenetic Proteins in the Context of Their Targets

  2017cites this paper
• Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells

  2017cites this paper
• Reprogramming acute myeloid leukemia into sensitivity for retinoic-acid-driven differentiation.

  2017cites this paper
• Patient with a short history of hemoptysis, fever and melena

  2017cites this paper
• Molecular mechanisms underlying the action of histone deacetylases inhibitors (HDACIs) in ovarian cancer

  2017cites this paper
• Epigenetics: Bioprobes that Target Epigenetic Modifications

  2017cites this paper
• An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts

  2016cites this paper
• Crosstalk Between DNA Methylation and Chromatin Structure

  2016cites this paper
• Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox-mediated mechanisms

  2015cites this paper
• Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development

  2015cites this paper
• A co-clinical platform to accelerate cancer treatment optimization.

  2015cites this paper
• Epigenetic drugs for cancer therapy

  2015cites this paper
• Akute myeloische Leukämie

  2015cites this paper
• Histone Deacetylase Inhibitor as a Novel Anticancer Agent: A Review

  2015cites this paper
• ATOH1 Can Regulate the Tumorigenicity of Gastric Cancer Cells by Inducing the Differentiation of Cancer Stem Cells

  2015cites this paper
• Acute Promyelocytic Leukaemia: From a Specific Translocation to Cure by Targeted Therapies

  2015cites this paper
• Vorinostat—An Overview

  2015cites this paper
• Core‐binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy

  2014cites this paper
• Epigenetics in the hematologic malignancies

  2014cites this paper
• Unlocking the potential of retinoic acid in anticancer therapy

  2014cites this paper
• Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells

  2014cites this paper
• Of model pets and cancer models: an introduction to mouse models of cancer.

  2014cites this paper
• Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnsition to targeted therapies

  2014influential citation
• Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy

  2014cites this paper
• One mouse, one patient paradigm: New avatars of personalized cancer therapy.

  2014cites this paper
• Suberoylanilide hydroxamic acid (vorinostat): its role on equine corneal fibrosis and matrix metalloproteinase activity.

  2014cites this paper
• Promyelocytic Leukemia Zinc Finger-Retinoic Acid Receptor α (PLZF-RARα), an Oncogenic Transcriptional Repressor of Cyclin-dependent Kinase Inhibitor 1A (p21WAF/CDKN1A) and Tumor Protein p53 (TP53) Genes*

  2014cites this paper
• Decitabine and SAHA-Induced Apoptosis Is Accompanied by Survivin Downregulation and Potentiated by ATRA in p53-Deficient Cells

  2014cites this paper
• Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases.

  2014cites this paper
• Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.

  2013cites this paper
• Inhibition of the NAD-Dependent Protein Deacetylase SIRT2 Induces Granulocytic Differentiation in Human Leukemia Cells

  2013cites this paper
• OXIDATIVE STRESS BASED STRATEGIES FOR ENHANCING THE EFFICACY OF HISTONE DEACETYLASE INHIBITORS (HDACi)

  2013cites this paper
• suppress differentiation into osteoclasts but not into macrophages Two histone deacetylase inhibitors, trichostatin A and sodium butyrate,

  2013cites this paper
• Expression of Leukemia-Associated Fusion Proteins Increases Sensitivity to Histone Deacetylase Inhibitor–Induced DNA Damage and Apoptosis

  2013cites this paper
• Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells

  2013cites this paper
• for refractory cutaneous T-cell lymphoma (CTCL) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA)

  2013cites this paper
• Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy

  2013cites this paper
• Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia

  2013cites this paper
• Treatment strategies for melanoma: pharmacological and toxicological action mechanisms of combined therapies

  2013cites this paper
• DNA Methylation and Histone Deacetylation: Interplay and Combined Therapy in Cancer

  2012cites this paper
• Dual regulation of P-glycoprotein expression by Trichostatin A in cancer cell lines

  2012cites this paper
• Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter‐associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells

  2012cites this paper
• Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine

  2012cites this paper
• Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL

  2012cites this paper
• Phase II Trial of Vorinostat plus Tacrolimus & Mycophenolate to prevent Graft versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant Blood and Marrow Transplantation Program University of Michigan Comprehensive Cancer Center

  2012cites this paper
• Synthesis and biological evaluation of novel AM80 derivatives as antileukemic agents

  2012cites this paper
• Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition

  2012cites this paper
• Strategies To Modulate Heritable Epigenetic Defects in Cellular Machinery: Lessons from Nature

  2012influential citation
• Effects of PPARγ Ligands on Leukemia

  2012cites this paper
• Pharmacological and Toxicological Advances in PPAR-Related Medicines

  2012cites this paper
• 5 Epigenetics and Targeted Therapy in Acute Leukemia

  2012cites this paper
• All-trans retinoic acid in the treatment of pediatric acute promyelocytic leukemia

  2012cites this paper
• The Development and Use of Genetically Tractable Preclinical Mouse Models

  2012cites this paper
• The Recognition of N-Glycans by the Lectin ArtinM Mediates Cell Death of a Human Myeloid Leukemia Cell Line

  2011cites this paper
• The APL paradigm and the "co-clinical trial" project.

  2011influential citation
• Acute Promyelocytic Leukemia: Manifestations and Therapy

  2011cites this paper
• The Role of Natural Killer Cells in the Context of Oncolytic Herpes Simplex Virotherapy for Glioblastoma

  2011cites this paper
• Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells

  2011cites this paper
• Epigenomics of leukemia: from mechanisms to therapeutic applications.

  2011cites this paper
• Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer

  2011cites this paper
• Epigenetics and Targeted Therapy in Acute Leukemia

  2011cites this paper
• Promises and challenges of anticancer drugs that target the epigenome.

  2011cites this paper
• The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias

  2011cites this paper
• Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells

  2011cites this paper
• Retinoids, retinoic acid receptors, and cancer.

  2011cites this paper
• Histone deacetylase inhibitors regulate the proteasomal degradation of oncoproteins

  2011cites this paper
• Histone deacetylase inhibitors.

  2011cites this paper
• EVI1 up-regulates the stress responsive gene SIRT1 which triggers deacetylation and degradation of EVI1.

  2011cites this paper
• The Histone Deacetylase Inhibitor, Vorinostat, Reduces Tumor Growth at the Metastatic Bone Site and Associated Osteolysis, but Promotes Normal Bone Loss

  2010cites this paper
• Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

  2010cites this paper
• The DAC system and associations with acute leukemias and myelodysplastic syndromes

  2010cites this paper
• An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with Mitomycin-C and a histone deacetylase inhibitor

  2010cites this paper
• Histone deacetylases and epigenetic therapies of hematological malignancies.

  2010cites this paper